Table 1.
Patient Characteristics at Study Entry
| Characteristics | TAHOD, n = 3356 n (%) |
AHOD, n = 2312 n (%) |
Pa |
|---|---|---|---|
| Age (years) | |||
| Mean | 38 | 43 | <.001 |
| <30 | 565 (16.8) | 154(6.6) | <.001 |
| 30–40 | 1564 (46.6) | 852 (36.8) | |
| 40–50 | 838 (25.0) | 800 (34.6) | |
| 50–60 | 274 (8.1) | 376 (16.3) | |
| >60 | 115 (3.4) | 130 (5.6) | |
| Sex | |||
| Male | 2393(71.3) | 2171(93.9) | <.001 |
| Female | 960 (28.6) | 134 (5.8) | |
| Transgender | 3 (0.09) | 7 (0.3) | |
| HIV exposure category | |||
| Homosexual contact ± IDU | 652 (19.4) | 1891 (81.8) | <.001 |
| IDU ± heterosexual | 123 (3.7) | 56 (2.4) | |
| Heterosexual | 2326 (69.3) | 212 (9.2) | |
| Other | 248 (7.4) | 127 (5.5) | |
| Missing | 7 (0.2) | 26 (1.1) | |
| Hepatitis B coinfection | |||
| Negative | 2024 (60.3) | 1823 (78.8) | <.001 |
| Positive | 239 (7.1) | 119 (5.1) | |
| Missing/never tested | 1093 (32.5) | 370 (16.0) | |
| Hepatitis C coinfection | |||
| Negative | 1817 (54.1) | 1782 (77.0) | <.001 |
| Positive | 191 (5.7) | 273 (11.8) | |
| Missing/never tested | 1348 (40.2) | 257 (11.1) | |
| HIV RNA <500 copies/mL | 1615 (48.1) | 1373(59.4) | <.001 |
| Prior AIDS at study entry | 1825 (46.8) | 511 (20.3) | <.001 |
| Median CD4 count per mm3 (IQR) | 259 (144–399) | 432 (262–640) | <.001b |
| ART Class at baseline | |||
| NRTI | 3192 (95.1) | 2030 (87.8) | <.005 |
| NNRTI | 2549 (75.6) | 1126 (48.7) | |
| PI | 760 (22.6) | 971 (42.0) | |
| Other | 9 (0.3) | 20 (0.9) | |
| Median duration of cART in months (IQR) | 13 (2.3–30.3) | 32 (10.3–45.6) | <.001b |
a
Comparison by t-test for continuous variables and the χ2 test for noncontinuous variables.
b
Comparison by Wilcoxon rank-sum test.
Abbreviations: TAHOD, TREAT Asia HIV Observational Database; AHOD, Australian HIV Observational Database; IDU, Intravenous drug user; IQR, inter-quartile range; CD4 count refers to CD4 T-cell count; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.